Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 51 to 75 of 306

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]	Technology appraisal guidance
Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]	Technology appraisal guidance
DB-OTO for Hearing loss [TSID12321]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID6688]	Technology appraisal guidance
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis [TSID11981]	Technology appraisal guidance
Deucravacitinib for treating active Sjogren's syndrome [TSID12342]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Digital AI tools in histopathology (breast and prostate cancer)	Health technology evaluation
Digital tools and platforms to support the early detection and initial diagnosis of hearing loss	Health technology evaluation
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance
Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]	Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]	Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]	Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]	Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]	Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]	Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]	Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]	Technology appraisal guidance
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]	Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]	Technology appraisal guidance

Results per page

10
25
50
All